{"name":"Aeras","slug":"aeras","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"AERAS-402","genericName":"AERAS-402","slug":"aeras-402","indication":"Other","status":"phase_2"},{"name":"AERAS-402 1.0 x 10^11 vp","genericName":"AERAS-402 1.0 x 10^11 vp","slug":"aeras-402-1-0-x-10-11-vp","indication":"Other","status":"phase_1"},{"name":"AERAS-402 1.5 x 10^10 vp","genericName":"AERAS-402 1.5 x 10^10 vp","slug":"aeras-402-1-5-x-10-10-vp","indication":"Other","status":"phase_1"},{"name":"AERAS-402 3 x 10^9 vp","genericName":"AERAS-402 3 x 10^9 vp","slug":"aeras-402-3-x-10-9-vp","indication":"Other","status":"phase_2"},{"name":"AERAS-402 3.0 x 10^10 vp","genericName":"AERAS-402 3.0 x 10^10 vp","slug":"aeras-402-3-0-x-10-10-vp","indication":"Other","status":"phase_1"},{"name":"AERAS-422","genericName":"AERAS-422","slug":"aeras-422","indication":"Other","status":"phase_1"},{"name":"BCG Tice","genericName":"BCG Tice","slug":"bcg-tice","indication":"Other","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"AERAS-402 3 x 10^10 vp","genericName":"AERAS-402 3 x 10^10 vp","slug":"aeras-402-3-x-10-10-vp","indication":"Tuberculosis prevention","status":"phase_2"},{"name":"AERAS-402 3 x 10^8 vp","genericName":"AERAS-402 3 x 10^8 vp","slug":"aeras-402-3-x-10-8-vp","indication":"Tuberculosis prevention (boost vaccination in BCG-primed individuals)","status":"phase_2"},{"name":"AERAS-404","genericName":"AERAS-404","slug":"aeras-404","indication":"Tuberculosis","status":"phase_2"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Candida Skin Test Antigen","genericName":"Candida Skin Test Antigen","slug":"candida-skin-test-antigen","indication":"Assessment of cell-mediated immune function in immunocompromised patients","status":"marketed"}]}],"pipeline":[{"name":"AERAS-402","genericName":"AERAS-402","slug":"aeras-402","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AERAS-402 1.0 x 10^11 vp","genericName":"AERAS-402 1.0 x 10^11 vp","slug":"aeras-402-1-0-x-10-11-vp","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AERAS-402 1.5 x 10^10 vp","genericName":"AERAS-402 1.5 x 10^10 vp","slug":"aeras-402-1-5-x-10-10-vp","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AERAS-402 3 x 10^10 vp","genericName":"AERAS-402 3 x 10^10 vp","slug":"aeras-402-3-x-10-10-vp","phase":"phase_2","mechanism":"AERAS-402 is a vaccine designed to stimulate an immune response against tuberculosis.","indications":["Tuberculosis prevention"],"catalyst":""},{"name":"AERAS-402 3 x 10^8 vp","genericName":"AERAS-402 3 x 10^8 vp","slug":"aeras-402-3-x-10-8-vp","phase":"phase_2","mechanism":"AERAS-402 is a replication-deficient adenovirus vector vaccine that expresses Mycobacterium tuberculosis antigens to stimulate immune responses against tuberculosis.","indications":["Tuberculosis prevention (boost vaccination in BCG-primed individuals)","Tuberculosis prevention in HIV-positive individuals"],"catalyst":""},{"name":"AERAS-402 3 x 10^9 vp","genericName":"AERAS-402 3 x 10^9 vp","slug":"aeras-402-3-x-10-9-vp","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AERAS-402 3.0 x 10^10 vp","genericName":"AERAS-402 3.0 x 10^10 vp","slug":"aeras-402-3-0-x-10-10-vp","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AERAS-404","genericName":"AERAS-404","slug":"aeras-404","phase":"phase_2","mechanism":"AERAS-404 is a vaccine designed to protect against tuberculosis.","indications":["Tuberculosis"],"catalyst":""},{"name":"AERAS-422","genericName":"AERAS-422","slug":"aeras-422","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BCG Tice","genericName":"BCG Tice","slug":"bcg-tice","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Candida Skin Test Antigen","genericName":"Candida Skin Test Antigen","slug":"candida-skin-test-antigen","phase":"marketed","mechanism":"Candida skin test antigen is an intradermal diagnostic agent that elicits a delayed-type hypersensitivity reaction to assess cell-mediated immune function.","indications":["Assessment of cell-mediated immune function in immunocompromised patients","Evaluation of delayed-type hypersensitivity response"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPY3pRUDNCa3hhdFlGTGVjRlRLdGQ2QjJfdGdWQzNhckpfZGtfZGlUNjdKOElNUzloR3djMkxlMGlsOTJqblY3Ny1hUzF6TEJudjBzdUJpbkY2S0RDQUtVdzZkUl9oNmJ6dXRRd3NMYndYTkJNQWgwd3Q0WW1aQjBwOTc5eFQ2R2dheWJhazd6QS1WMy1CWGdNWnhrVm1pSTZYQ1dQRzBiTWhZNFhRU0lDcA?oc=5","date":"2023-10-04","type":"earnings","source":"ProPublica","summary":"How a Big Pharma Company Stalled a Potentially Lifesaving Vaccine in Pursuit of Bigger Profits - ProPublica","headline":"How a Big Pharma Company Stalled a Potentially Lifesaving Vaccine in Pursuit of Bigger Profits","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPU1BCdDNhU1VmWHJsMDRHVUJyNm1WWVFFbWRWcm1la013OERJdlpsNGFab2Fwd1FuQTNHSkRPWXJUUGtwY1FkanVXTHNSVEtWRmVGRUVFVGEzNHFoaTlISXRqT3g0bVlhaF9LbGtBWGlxT3lsaHJaUlZJd1JlcXJFc1ZiU1I4OXhOTmtBVTVGUUtXZGNXbVN5b1F3dVd2Qm1sQVhVcXZGWkxkLXoxYmhkLTk4RFE2cWRNZDMwcVR2VzQ?oc=5","date":"2022-05-11","type":"pipeline","source":"Fierce Biotech","summary":"Inovio CEO departs after bumpy ride in COVID vaccines market - Fierce Biotech","headline":"Inovio CEO departs after bumpy ride in COVID vaccines market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQV0FJZm9UMXJ6OHdUcG1CS1BCTmhzbWtlUHNrN210WlZMRTNPcTVaXzVUZTBjYmFkQktrc3RZV0RydVM2VDhmcmw4VEs2ekhSelQ4YXh3MzAwMV80anhrZ0pSX0FvcXAtZVFyQlhyMktLTFpRck5INXFYZ0prX3I0Q3kyQW9QSjhmVTJCMUxidDA2djk0SVh5NmNMYw?oc=5","date":"2018-10-01","type":"deal","source":"IAVI","summary":"IAVI Acquires Aeras TB Vaccine Clinical Programs and Assets - IAVI","headline":"IAVI Acquires Aeras TB Vaccine Clinical Programs and Assets","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"phase_2":5,"phase_1":4,"marketed":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}